Kaiser Permanente's evaluation and management of biotech drugs: assessing, measuring, and affecting use
| Autor: | Richard Wagner, Lori Potter, Mirta Millares, C. Douglas Monroe, Anthony Barrueta |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
business.industry
Delivery of Health Care Integrated Health Policy media_common.quotation_subject Health Maintenance Organizations Evidence analysis Insurance Pharmaceutical Services United States Health care delivery Biotechnology Negotiation Multidisciplinary approach Pharmacogenetics Health care Medicine Effective treatment Humans business health care economics and organizations media_common |
| Zdroj: | Health affairs (Project Hope). 25(5) |
| ISSN: | 1544-5208 |
| Popis: | Two decades into the age of high-cost biotechnology medications, health care organizations are challenged to provide safe, effective treatment while managing costs. In a market lacking generic biotech drugs, health care organizations have few opportunities to negotiate reduced pricing; other strategies must be devised to manage use. Kaiser Permanente leverages its integrated health care delivery system to deploy management tools for costly therapies: evidence analysis, usage measurements, and multidisciplinary planning. Evidence-based medicine and realization of value provided by new therapies will depend on data capture and outcomes measurement, tools that are crucial to Kaiser Permanente’s management of biotechnologies and effective use of members’ financial resources. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|